|
|
|
Insider
Information: |
Berkman Charles S |
Relationship: |
Chief Legal Officer |
City: |
San Diego |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
2 |
|
Direct
Shares |
316,442 |
|
Indirect Shares
|
0 |
|
|
Direct
Value |
$3,311,271 |
|
|
Indirect Value
|
$0 |
|
|
Total
Shares |
316,442 |
|
|
Total
Value |
$3,311,271 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
3
|
Stock
price went up :
|
0
|
1
|
Stock
price went down : |
0
|
2
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
-14.7%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Ligand Pharmaceuticals Inc |
LGND |
Former Executive Officer |
2022-11-01 |
23,825 |
|
0 |
Premium* |
|
OmniAb, Inc |
OABI |
Chief Legal Officer |
2024-04-08 |
292,617 |
2022-11-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
94 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 3 of 4
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
LGND |
Ligand Pharmaceuticals In... |
SVP, Gen. Counsel & Secretary |
|
2018-06-29 |
4 |
A |
$117.84 |
$21,210 |
D/D |
180 |
27,763 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
SVP, Gen. Counsel & Secretary |
|
2018-09-04 |
4 |
AS |
$254.99 |
$4,951,065 |
D/D |
(19,417) |
27,763 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
SVP, Gen. Counsel & Secretary |
|
2018-09-04 |
4 |
OE |
$21.92 |
$1,358,796 |
D/D |
19,417 |
47,180 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
SVP, Gen. Counsel & Secretary |
|
2018-09-17 |
4 |
AS |
$250.69 |
$705,181 |
D/D |
(2,813) |
27,763 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
SVP, Gen. Counsel & Secretary |
|
2018-09-17 |
4 |
OE |
$100.38 |
$282,369 |
D/D |
2,813 |
30,576 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
SVP, Gen. Counsel & Secretary |
|
2018-10-11 |
4 |
OE |
$14.47 |
$28,940 |
D/D |
2,000 |
29,763 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
SVP, Gen. Counsel & Secretary |
|
2018-10-24 |
4 |
OE |
$14.47 |
$65,462 |
D/D |
3,900 |
33,663 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
SVP, Gen. Counsel & Secretary |
|
2018-12-17 |
4 |
OE |
$21.92 |
$74,528 |
D/D |
3,400 |
37,063 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
SVP, Gen. Counsel & Secretary |
|
2019-01-10 |
4 |
OE |
$21.92 |
$187,029 |
D/D |
2,850 |
39,913 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
SVP, Gen. Counsel & Secretary |
|
2019-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
2,782 |
42,695 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
SVP, Gen. Counsel & Secretary |
|
2019-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,202 |
45,897 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
SVP, Gen. Counsel & Secretary |
|
2019-06-28 |
4 |
A |
$97.03 |
$17,659 |
D/D |
182 |
46,079 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
SVP, Gen. Counsel & Secretary |
|
2019-08-05 |
4 |
OE |
$56.26 |
$74,013 |
D/D |
1,093 |
47,172 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
SVP, Gen. Counsel & Secretary |
|
2019-12-20 |
4 |
D |
$105.87 |
$119,739 |
D/D |
(1,131) |
49,069 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
SVP, Gen. Counsel & Secretary |
|
2019-12-20 |
4 |
A |
$0.00 |
$0 |
D/D |
3,028 |
49,615 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
SVP, Gen. Counsel & Secretary |
|
2020-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
3,835 |
52,904 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
SVP, Gen. Counsel & Secretary |
|
2020-02-15 |
4 |
D |
$97.23 |
$85,660 |
D/D |
(881) |
52,023 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
SVP, Gen. Counsel & Secretary |
|
2020-06-04 |
4 |
S |
$118.59 |
$1,321,775 |
D/D |
(11,146) |
40,877 |
0 |
% |
|
LGND |
Ligand Pharmaceuticals In... |
SVP, Gen. Counsel & Secretary |
|
2020-06-30 |
4 |
A |
$89.03 |
$21,189 |
D/D |
238 |
41,115 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
SVP, Gen. Counsel & Secretary |
|
2021-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,736 |
44,342 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
SVP, Gen. Counsel & Secretary |
|
2021-01-25 |
4 |
D |
$156.01 |
$208,943 |
D/D |
(1,339) |
43,512 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
SVP, Gen. Counsel & Secretary |
|
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
3,491 |
47,003 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
SVP, Gen. Counsel & Secretary |
|
2021-02-04 |
4 |
S |
$178.50 |
$3,230,376 |
D/D |
(18,097) |
28,906 |
0 |
% |
|
LGND |
Ligand Pharmaceuticals In... |
SVP, Gen. Counsel & Secretary |
|
2021-02-15 |
4 |
D |
$172.46 |
$175,047 |
D/D |
(1,015) |
27,891 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
SVP, Gen. Counsel & Secretary |
|
2022-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
6,237 |
34,128 |
0 |
- |
|
94 Records found
|
|
Page 3 of 4 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|